Ensitrelvir Reduced the Risk for COVID-19 by 67%

Ensitrelvir, an antiretroviral being developed to prevent COVID-19, reduced the risk of developing the infection by 67% in uninfected people after exposure to SARS-CoV-2 compared with placebo at day 10.